Morten Vigeland commenced with ImpediMed in April 2011, was promoted to Vice President of Global Finance in March 2013 and to CFO in September 2013. Morten has more than 15 years of experience in financial management in the medical technology industry. Previous role includes Chief Financial Officer of Access Scientific, Inc., a medical device company, where he completed multiple rounds of financing and corporate deals with C.R. Bard, Inc. and Teleflex, Inc.
Morten has a strong background in operations, finance and accounting, and a proven track record of strong financial management for start-ups and emerging growth companies, both private and public.
His early experience was serving as Associate Director of Finance with Applied Molecular Evolution (AME), where he supported the IPO that raised more than $100 million. AME later merged with Eli Lilly & Co. Morten was the Corporate Controller for Venetec International, Inc. in its emerging growth period. Venetec was acquired by C.R. Bard, Inc. for $167 million in 2006, and Morten served as the Corporate Controller for C.R. Bard, Inc.’s StatLock Division post acquisition.
Morten holds an MBA from California State University, and a Bachelor of Science, Business Administration, Finance from the University of Colorado.